Analytical Data
-
Gene name
HMGN2
- Application
-
Alternative Names
High mobility group nucleosome-binding domain-containing protein 2
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P05204
-
Expression Region
1-90aa
-
Molecular Weight
36.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HMGN2 is a member of the high mobility group nucleosome-binding protein family, known for its role in modulating chromatin structure and enhancing gene expression. It interacts with the nucleosome core, influencing the accessibility of DNA to transcription factors, and plays a crucial role in various cellular processes, including differentiation, development, and stress responses. Researchers have identified that HMGN2 is involved in tumor progression and immune responses, making it a potential biomarker and therapeutic target in cancer research. Additionally, its ability to regulate the epigenetic landscape raises interest in understanding how it can be manipulated for therapeutic purposes. The expression and function of recombinant HMGN2 proteins are therefore being investigated to unravel its mechanistic roles in cellular processes and to evaluate its potential applications in gene therapy and regenerative medicine. The production of recombinant HMGN2 not only facilitates functional studies but also opens avenues for creating novel biopharmaceuticals. Researchers are focusing on optimizing expression systems and purification techniques to obtain high-quality HMGN2 proteins for detailed biochemical and biophysical characterization. Through these studies, a deeper understanding of HMGN2’s role in chromatin dynamics and its implications in disease contexts can be achieved, paving the way for innovative therapeutic strategies targeting epigenetic regulation.
